Bevimi wins up to $2m ARPA-H grant to map early Alzheimer's biology

The Greenwich-based cognitive health company will run an 18-month, 150-person decentralised study measuring Alzheimer's-related biomarkers in pre-diagnosis adults.

A robotic arm with a multi-channel pipette performs liquid handling on microplates positioned on a lab bench in a brightly lit, modern laboratory.

Bevimi, a brain health and nutritional-science company founded in 2025, has been selected to receive up to $2 million from the Advanced Research Projects Agency for Health (ARPA-H) to conduct PS36-PRISMM, an 18-month research programme examining biological changes linked to subjective cognitive decline and early Alzheimer's-related pathology.

The study will enrol 150 US adults aged 45 to 70 who report self-observed changes in memory or cognition without a formal clinical diagnosis. Enrolment is targeted to complete within approximately six months of programme launch, with participants followed for 24 weeks of active data collection.

The study design

PRISMM (Pre-disease Resilience and Immune Stratification Multimodal Map) is structured as a randomised, double-blind, placebo-controlled trial evaluating Bevimi's Uno Protect, a once-daily nutritional beverage. The protocol is largely remote: blood samples will be collected either at designated sites or by mobile phlebotomists visiting participants at home, cognitive assessments will be administered digitally, and participants will complete regular check-ins through a digital platform.

At baseline, week 12 and week 24, researchers plan to collect more than 15,000 molecular measurements per participant. The planned measurement battery spans blood-based proteomic profiling, key Alzheimer's-associated biomarkers including p-tau217, GFAP and NfL, APOE genotyping, and oral and gut microbiome sequencing. P-tau217 in particular has attracted significant attention as a blood-based marker correlated with amyloid and tau pathology. Statistical analysis is to be conducted by independent clinical research organisation People Science rather than Bevimi, with study predictions preregistered before data unblinding.

Glen Coppersmith, Director of ARPA-H's Proactive Health Office, said the programme is "designed to combine decentralised clinical research with deep longitudinal biological measurement to generate new data on cognitive change before a clinical diagnosis."

As a deliverable to ARPA-H, Bevimi will also deposit a de-identified research dataset, a study-methods playbook and a cross-validation of three proteomic platforms into a shared research repository. The agency says it expects the resource to inform future decentralised, multi-omic studies.

Market and regulatory context

The study sits at an increasingly active intersection of consumer wellness and serious Alzheimer's research. Regulatory and scientific pressure has been growing for supplement and functional-food companies to produce rigorous clinical evidence rather than rely on structure-function claims, and ARPA-H's involvement lends the programme a credibility that company-funded nutritional studies rarely carry. The agency was established by Congress in 2022 specifically to fund high-risk, high-reward health research that falls outside traditional NIH remit, and its Proactive Health Office has a stated focus on pre-disease biology.

The pre-clinical Alzheimer's space is drawing growing investment from pharmaceuticals and digital-health companies alike, driven partly by the commercial and scientific precedent set by amyloid-targeting therapies that gained FDA approval in recent years. Multi-omic longitudinal datasets of the kind PRISMM proposes to generate are in demand from drug developers and academic groups seeking to identify predictive biomarkers for intervention trials. Whether Bevimi's nutritional product shows a measurable effect on the molecular readouts will be central to the study's scientific credibility and the company's longer-term commercial positioning.

Bevimi co-founder and president Joel Dudley acknowledged the contrast with the broader supplement sector, saying the ARPA-H award gives the company "the opportunity to demonstrate that approach at meaningful scale." The Alzheimer's Association estimates that 7.4 million Americans aged 65 and older are currently living with clinical Alzheimer's dementia, a figure that underscores both the public health need and the commercial stakes in this research area.